Why the study?
Is high-dose dipyridamole echocardiography safe and feasible in elderly patients compared to younger patients referred for evaluation of coronary artery disease?
Is high-dose dipyridamole echocardiography safe and feasible in elderly patients compared to younger patients referred for evaluation of coronary artery disease?
High-dose dipyridamole echocardiography is a feasible and generally safe noninvasive method for evaluating coronary artery disease in elderly patients, though they experience more dyspnea than younger patients.
Supports dipyridamole echocardiography in elderly patients; leaves open prospective validation before routine CAD use.
The authors prospectively studied the feasibility and safety of high-dose dipyridamole echocardiography in 166 patients (77 younger and 89 elderly patients) referred for clinical evaluation of coronary artery disease. Echocardiographic examinations were adequate for analysis of parameters considered in 135 of the 166 patients (81.3%; 73 elderly, 62 younger patients). The feasibility of dipyridamole echocardiography test was 80.5% in young and 82% in elderly patients (P = ns). The incidence of side effects during dipyridamole echocardiography was similar in the two groups, except for dyspnea, which was observed in 20.5% of older and 3.2% of younger patients (p < 0.05). These data demonstrate that the dipyridamole test combined with echocardiographic monitoring of regional myocardial contractility may be considered a valid noninvasive method of evaluating coronary artery disease in the elderly.
No takes yet. Share an insight, caveat, or question.
Cicatiello et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: